Telix executives to speak at UBS biopharma conference

Behrenbruch, the company’s managing director and group CEO, and Valeix, CEO of Therapeutics, will take part in the conference discussion. The webcast will be available through Telix’s Investor Relations website. Registration details are at https://ir.telixpharma.com/events-presentations.

Telix is a Melbourne-headquartered commercial-stage radiopharmaceutical company developing targeted theranostics for cancer. Its diagnostic products include Illuccix, available in 22 countries including the United States, and Gozellix and Pixclara, both approved by the U.S. Food and Drug Administration for imaging uses. The company also has three investigational therapeutic candidates in pivotal-stage trials, targeting prostate cancer, recurrent glioblastoma and kidney cancer.